Efficacy and safety of N-acetylcysteine in treatment of severe alcoholic hepatitis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 12
Abstract
[Objective] To investigate the efficacy and safety of N-acetylcysteine （NAC） in the treatment of severe alcoholic hepatitis （SAH）， and to provide a basis for clinical medication for SAH. [Methods] A prospective randomized controlled trial was conducted among 172 SAH patients with a Maddrey discriminant function score of >32 points who were recruited by The Fifth Medical Center of Chinese PLA General Hospital from June 2015 to June 2018， and these patients were divided into NAC group with 84 patients and control group with 86 patients. NAC （8 g/day， 28 days） was assessed in terms of its safety in SAH patients， its impact on 28-day biochemical parameters， and its role in improving 28- and 180-day survival rates. A further analysis was performed to investigate the effect of NAC on the 28- and 180-day survival rates of SAH patients with acute-on-chronic liver failure （ACLF-SAH patients） and those without acute-on-chronic liver failure （non-ACLF-SAH patients）. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate independent influencing factors. [Results] No serious adverse events were observed during NAC treatment， suggesting that NAC had a good safety profile. Compared with the control group， NAC did not significantly improve the 28-day biochemical parameters （all P>0.05） and survival rate of SAH patients （P=0.081）， but it could improve the 180-day survival rate of SAH patients （67.4% vs 81.0%， χ2=4.280， P=0.039）. NAC did not improve the 28- and 180-day survival rates of ACLF-SAH patients （both P>0.05）； NAC did not improve the 28-day survival rate of non-ACLF-SAH patients （P>0.05）， but it could improve the 180-day survival rate of these patients （68.4% vs 88.9%， χ2=4.883， P=0.027）. The multivariate Cox regression survival analysis showed that NAC treatment （hazard ratio ［HR］=2.530， 95% confidence interval ［CI］： 1.334 — 4.796， P=0.004，）， Maddrey discriminant function score （HR=3.852， 95%CI： 2.032 — 7.304， P<0.001）， and serum sodium level （HR=1.948， 95%CI： 1.079 — 3.517， P=0.027） were independent influencing factors for 180-day survival rate in SAH patients. [Conclusion] NAC has a good safety profile in the treatment of SAH and can improve the 180-day survival rate of SAH patients， and in particular， non-ACLF-SAH patients can benefit from NAC treatment in terms of middle- and long-term survival rates.
Authors and Affiliations
Fangjiao SONG, Tianjiao XU, Yirui YIN, Hua TIAN, Sa LYU, Shaoli YOU, Shaojie XIN, Bing ZHU
Keywords
Related Articles
- EP ID EP753946
- DOI 10.12449/JCH241219
- Views 42
- Downloads 0
Risk factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury and construction of a nomogram model
[Objective] To investigate the predictive factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury （AKI）， and to establish and validate a nomogram predict...
Role of statins in chronic liver disease
Chronic liver disease is the “devil’s trilogy” in which the liver progresses from inflammation and fibrosis to liver cirrhosis and hepatocellular carcinoma， which poses a great challenge for hepatologists worldwide. Sta...
New advances in antiviral therapy during pregnancy to block mother-to-child transmission of hepatitis B virus
Mother-to-child transmission of hepatitis B virus （HBV） is one of the primary causes of the high disease burden of chronic hepatitis B in China， and blocking this route of transmission has an important strategic signi...
Feasibility and safety of laparoscopic radical surgery for intrahepatic cholangiocarcinoma
Endoscopic techniques has been widely used in radical surgical resection of various tumors， but there are still controversies over the application of laparoscopy in radical treatment of intrahepatic cholangiocarcinoma....
Efficacy of des-γ-carboxy-prothrombin in the diagnosis of hepatocellular carcinoma and its association with the clinical features of hepatocellular carcinoma
[Objective] To investigate the value of des-γ-carboxy-prothrombin （DCP） in hepatocellular carcinoma （HCC）. [Methods] A retrospective analysis was performed for the clinical data of 179 HCC patients who were admitted...